May 20, 2011
For immediate release
Contact: Gerry Ewing / 503-681-1654
The Tuality/OHSU Cancer Center and Westside Urology Associates will once again play host to a free PSA prostate screening event from 9 a.m. to noon, Saturday, June 11 at the cancer center at 299 SE 9th Ave. in Hillsboro. No registration is required.
Prostate cancer is the most common cancer in American men, according to the American Cancer Society. An estimated 217,730 new cases of prostate cancer will be diagnosed and 32,050 men will die of prostate cancer this year, according to society projections. While 1 man in 6 will be diagnosed with prostate cancer during his lifetime, only 1 man in 36 will die of prostate cancer.
Please join a discussion, beginning at 9 a.m., as physicians from the Tuality/OHSU Cancer Center and Westside Urology Associates share information about prostate cancer, its diagnosis, and treatment.
This will include information on prostate specific antigen (PSA) blood-test screenings and recent recommendations by the American Cancer Society regarding their use and what it means when elevated PSA levels are detected. This early-detection screening test is used extensively as a tool to help find the disease in its early stages.
Following the presentation, physicians and staff from the Tuality/OHSU Cancer Center, Westside Urology Associates, and Tuality Healthcare, will provide free PSA blood tests. Staff also will be on hand to help answer further questions and provide educational information on prostate cancer and treatment options.
Tests will be processed by Tuality’s Laboratory Services, and results will be analyzed by radiation oncology physicians from the Tuality/OHSU Cancer Center. Their conclusions will be mailed to the participating men and their primary-care physicians during the following week.
For more information, contact Tina Dickerson, director, Tuality/OHSU Cancer Center, at 503-681-4200. Or visit the center’s Website at www.tuality-ohsu-cancercenter.org.
Presented by Tuality Healthcare, Westside Urology Associates LLP, and the Tuality/OHSU Cancer Center.